Eishiro Mizukoshi Selected Research

EH0202

9/2004

An open-label study of administration of EH0202, a health-food additive, to patients with chronic hepatitis C.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Eishiro Mizukoshi Research Topics

Disease

50	Hepatocellular Carcinoma (Hepatoma) 03/2022 - 03/2006
45	Neoplasms (Cancer) 01/2022 - 03/2006
11	Fibrosis (Cirrhosis) 12/2021 - 06/2013
11	Chronic Hepatitis C 10/2020 - 09/2004
10	Non-alcoholic Fatty Liver Disease 01/2022 - 02/2010
9	Liver Cirrhosis (Hepatic Cirrhosis) 01/2022 - 02/2010
8	Infections 01/2022 - 06/2002
7	Inflammation (Inflammations) 01/2022 - 05/2010
6	Pancreatic Neoplasms (Pancreatic Cancer) 01/2021 - 09/2010
5	Neoplasm Metastasis (Metastasis) 02/2021 - 04/2013
5	Liver Neoplasms (Liver Cancer) 11/2019 - 04/2013
4	Liver Diseases (Liver Disease) 01/2022 - 06/2018
4	Fatty Liver 12/2021 - 01/2020
4	Alcoholic Fatty Liver 12/2021 - 06/2015
4	Hepatitis 08/2021 - 11/2004
4	Insulin Resistance 01/2020 - 11/2010
3	Adenocarcinoma 11/2020 - 05/2014
3	Melanoma (Melanoma, Malignant) 10/2020 - 05/2014
3	Disease Progression 03/2020 - 06/2016
3	Chronic Hepatitis B 06/2018 - 04/2016
3	Hepatitis C 11/2006 - 07/2004
2	Colitis 01/2022 - 11/2019
2	Cholangiocarcinoma 06/2021 - 11/2018
2	Thrombosis (Thrombus) 09/2020 - 12/2019
2	Stomach Neoplasms (Stomach Cancer) 01/2020 - 09/2010
2	Carcinogenesis 06/2018 - 11/2014
2	Hepatitis B 06/2018 - 01/2018
2	Necrosis 01/2016 - 05/2010
2	Type 2 Diabetes Mellitus (MODY) 10/2012 - 11/2010
2	Chronic Hepatitis (Chronic Active Hepatitis) 10/2012 - 11/2004
1	Dysbiosis 01/2022
1	Rupture 01/2022

Drug/Important Bio-Agent (IBA)

17	AntigensIBA 01/2022 - 03/2006
11	Peptides (Polypeptides)IBA 01/2022 - 06/2002
11	InterferonsIBA 02/2021 - 09/2004
10	Sorafenib (BAY 43-9006)FDA Link 02/2021 - 11/2014
9	Biomarkers (Surrogate Marker)IBA 03/2022 - 08/2012
7	Antiviral Agents (Antivirals)IBA 01/2022 - 07/2004
7	EnzymesIBA 01/2020 - 06/2006
6	EpitopesIBA 01/2020 - 06/2002
6	Telomerase (Telomerase Reverse Transcriptase)IBA 04/2019 - 06/2006
5	Proteins (Proteins, Gene)FDA Link 01/2022 - 11/2010
5	Fatty Acids (Saturated Fatty Acids)IBA 07/2020 - 10/2012
5	Pharmaceutical PreparationsIBA 03/2020 - 09/2012
5	alpha-Fetoproteins (alpha-Fetoprotein)IBA 02/2020 - 03/2006
5	CytokinesIBA 11/2019 - 11/2004
4	Therapeutic UsesIBA 12/2021 - 10/2012
4	Immune Checkpoint InhibitorsIBA 02/2021 - 01/2019
4	Epithelial Cell Adhesion MoleculeIBA 01/2021 - 04/2013
4	DNA (Deoxyribonucleic Acid)IBA 01/2021 - 11/2010
4	RNA (Ribonucleic Acid)IBA 04/2019 - 09/2004
4	Ribavirin (Virazole)FDA LinkGeneric 03/2014 - 02/2006
3	Gemcitabine FDA Link 11/2020 - 11/2018
3	gadolinium ethoxybenzyl DTPA FDA Link 06/2020 - 10/2014
3	Adrenal Cortex Hormones (Corticosteroids)IBA 02/2020 - 01/2017
3	Fetal Proteins (Fetoprotein)IBA 01/2020 - 01/2016
3	Messenger RNA (mRNA)IBA 04/2019 - 11/2010
3	Glucose (Dextrose)FDA LinkGeneric 05/2014 - 11/2010
3	Neoplasm Antigens (Tumor Antigens)IBA 04/2014 - 05/2010
2	Transforming Growth Factor beta (TGF-beta)IBA 01/2022 - 01/2021
2	LDN-212854IBA 01/2022 - 01/2021
2	Protein Subunit VaccinesIBA 01/2022 - 12/2015
2	AlbuminsIBA 08/2021 - 10/2012
2	Serum AlbuminIBA 08/2021 - 01/2017
2	NitrogenIBA 02/2021 - 01/2019
2	regorafenibIBA 02/2021 - 11/2018
2	lenvatinibIBA 02/2021 - 07/2020
2	Alanine Transaminase (SGPT)IBA 01/2020 - 12/2019
2	palmitoleic acidIBA 10/2019 - 02/2015
2	wisteria lectinIBA 06/2019 - 06/2018
2	Carrier Proteins (Binding Protein)IBA 06/2019 - 06/2018
2	squamous cell carcinoma-related antigenIBA 11/2018 - 01/2017
2	Multidrug Resistance-Associated ProteinsIBA 11/2018 - 12/2015
2	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 11/2018 - 12/2017
2	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2017 - 11/2013
2	LigandsIBA 01/2016 - 08/2010
2	VaccinesIBA 06/2006 - 06/2002
2	HLA-A Antigens (HLA-A)IBA 06/2006 - 03/2006
1	Bone Morphogenetic Protein ReceptorsIBA 01/2022
1	Amino Acids FDA Link 01/2022
1	rebamipideIBA 01/2022
1	LuciferasesIBA 01/2022
1	AcidsIBA 01/2022
1	Long Noncoding RNAIBA 01/2022
1	Choline (Choline Chloride)IBA 01/2022
1	SecretagoguesIBA 01/2022
1	CathepsinsIBA 01/2022
1	4-hydroxy-2-nonenal (4-hydroxynonenal)IBA 01/2022
1	MucinsIBA 01/2022
1	CarcinogensIBA 10/2021
1	Transaminases (Aminotransferases)IBA 05/2021

Therapy/Procedure

32	Therapeutics 08/2021 - 07/2004
21	Immunotherapy 01/2021 - 06/2002
13	Drug Therapy (Chemotherapy) 01/2021 - 04/2009
4	Radiofrequency Ablation 07/2020 - 08/2010
3	Cell- and Tissue-Based Therapy (Cell Therapy) 12/2021 - 01/2019
3	Aftercare (After-Treatment) 06/2018 - 09/2004
2	Lasers (Laser) 01/2021 - 12/2008
2	Glycemic Control 10/2012 - 02/2010
1	Heterologous Transplantation (Xenotransplantation) 10/2021